Our primary business activity is the research and development of innovative drugs for rare diseases. The selection of indications for new drug development focuses on unmet medical needs, targeting severe conditions with no available treatments and emerging therapeutic gaps. We aim to leverage our expertise in clinical and preclinical research, animal pharmacology and toxicology studies, regulatory compliance (domestic and international), intellectual property protection, global licensing, and extensive practical experience in specialty drug development in the U.S. Our mission is to develop novel and effective therapies that bring hope to patients, fulfilling our commitment to social responsibility.